Log In
Print
BCIQ
Print
Print this Print this
 

F598, SAR279356

  Manage Alerts
Collapse Summary General Information
Company Alopexx Pharmaceuticals LLC
DescriptionHuman mAb against poly-N-acetyl glucosamine (PNAG)
Molecular Target Poly-N-acetyl glucosamine (PNAG)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationBacterial infection
Indication DetailsTreat and prevent bacterial infection
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

$375.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today